ONE Bio Corp.
ONBI · Other OTC · USD
0,0005USD
0,00 (0,00 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 0,0005
- Vortag
- 0,0005
- Tagesspanne
- 0,0005 – 0,003
- 52 Wochen
- 0,0002 – 0,003
- Volumen
- 5764
- Ø Volumen
- 5508
- Börsenwert
- 4235 $
- KGV
- 0,0
- Gewinn je Aktie (TTM)
- 0,89
- Dividendenrendite
- 0,0 %
- Beta
- 6,0
- Nächste Zahlen
- –
Finanzen
| USD | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 |
|---|---|---|---|---|---|
| Umsatz | 52,3 Mio. | 22,07 Mio. | 78.240 | 578.590 | 207.507 |
| Herstellungskosten | 32,17 Mio. | 12,09 Mio. | 43.906 | 194.869 | 69.000 |
| Bruttogewinn | 20,13 Mio. | 9,98 Mio. | 34.334 | 383.721 | 138.505 |
| Forschung und Entwicklung | 259.878 | 378.497 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 6,18 Mio. | 2,15 Mio. | 59.064 | 333.717 | 129.544 |
| Operatives Ergebnis | 13,68 Mio. | 7,46 Mio. | −34.265 | 42.855 | −11.359,65 |
| EBITDA | 13,61 Mio. | 8,02 Mio. | −25.256 | −4382,27 | 132.324 |
| Nettogewinn | 8,68 Mio. | 4,77 Mio. | −42.136 | 37.258 | −3789,14 |
| Gewinn je Aktie (verwässert) | 1,35 | 0,93 | -0,01 | -0,01 | -0,06 |
Bewertung
Letzte 12 Monate
- KGV
- 0,0
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 0,0
- PEG
- -0,0
- Bruttomarge
- 38,5 %
- Operative Marge
- 26,2 %
- Nettomarge
- 16,6 %
- Verschuldungsgrad
- 0,5
- EV/EBITDA
- 0,7
- Eigenkapitalrendite
- 24,3 %
- Kapitalrendite (ROIC)
- 16,1 %
- Free-Cashflow-Rendite
- 108.922,1 %
| FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | |
|---|---|---|---|---|---|
| Bruttomarge | 38,5 % | 45,2 % | 43,9 % | 66,3 % | 66,7 % |
| Operative Marge | 26,2 % | 33,8 % | −43,8 % | 7,4 % | −5,5 % |
| Nettomarge | 16,6 % | 21,6 % | −53,9 % | 6,4 % | −1,8 % |
| KGV | 4,5 | 31,7 | -2.010,1 | 3.233,7 | -524,7 |
| Kurs-Umsatz-Verhältnis | 0,8 | 6,8 | 1.079,4 | 209,0 | 9,6 |
| Kurs-Buchwert-Verhältnis | 0,9 | 5,1 | -3.239,0 | 1.917,0 | 57,1 |
| Verschuldungsgrad | 0,5 | 0,6 | -0,9 | 1,3 | 1,4 |
| Liquidität 3. Grades | 1,5 | 1,6 | 0,4 | 7,9 | 1,2 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 48,34 Mio. | 163,27 Mio. | 84,47 Mio. | 120,88 Mio. | 2,03 Mio. |
| EV/EBITDA | 3,6 | 20,3 | -3.344,7 | -27.582,9 | 15,3 |
| Eigenkapitalrendite | 20,6 % | 16,2 % | 161,6 % | 59,1 % | −10,9 % |
| Kapitalrendite (ROIC) | 16,1 % | 10,8 % | 1.418,8 % | 20,7 % | −13,7 % |
| Free-Cashflow-Rendite | 11,7 % | −1,4 % | 0,0 % | 0,0 % | −1,4 % |
Wachstum
| FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | |
|---|---|---|---|---|---|
| Umsatz | +136,9 % | +28.112,2 % | −86,5 % | +178,8 % | +26,7 % |
| Bruttogewinn | +101,6 % | +28.979,6 % | −91,1 % | +177,0 % | +0,1 % |
| Operatives Ergebnis | +83,4 % | +21.867,8 % | −180,0 % | +477,3 % | +77,9 % |
| Nettogewinn | +81,8 % | +11.427,2 % | −213,1 % | +1.083,3 % | −121,8 % |
| Gewinn je Aktie | +45,2 % | +6.839,1 % | −112,3 % | +88,5 % | −122,7 % |
| Freier Cashflow | +313,8 % | −10.532,6 % | −49,6 % | +244,7 % | +39,1 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Gewinn je Aktie · Erwartet |
|---|
| Gewinn je Aktie · Tatsächlich |
| Abweichung |
| Umsatz · Tatsächlich |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 15. Sept. 20101:5
- 17. Nov. 20091:5
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
ACBMAcro Biomedical Co., Ltd.0,0260,00 %
AFFYAffymax, Inc.0,00080,00 %
AMBSAmarantus BioScience Holdings, Inc.0,00010,00 %
AXMPAXM Pharma, Inc.0,0001+9.900,00 %
BSSPBaseline Productions, Inc.0,00020,00 %
ITMCItoco Inc.0,00010,00 %
MLPHMolecular Pharmacology (USA), Ltd.0,0322+0,00 %
NSPDFNaturally Splendid Enterprises Ltd.0,040,00 %
Über das Unternehmen
ONE Bio Corp. functions as an agritech enterprise that, alongside its subsidiaries, employs eco-friendly manufacturing methods to develop and produce foundational chemicals, botanical extracts, health supplements, and organic goods. The company's operations are divided into two primary segments: Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE division is dedicated to the creation, production, and market introduction of bio-ecological and non-prescription items. These products are formulated using compounds extracted from tobacco leaves and various other plant sources. Its offerings encompass chemical extracts such as Solanesol and Coenzyme Q10, in addition to herbal extracts like Resveratrol, 5-Hydroxytryptophan, and Ganoderma Tea, alongside granular and powdered fertilizers. Distribution for CHE products within China's bio-health and raw chemical intermediates sectors occurs through a network of independent third-party distributors, academic institutions, and hospital research facilities. Meanwhile, the OP unit manufactures a diverse array of health and energy beverages for both consumer and commercial use, organic food products, and fertilizers. These products, primarily bamboo-based, are marketed within the People's Republic of China. Its portfolio includes standard and vacuum-packed canned bamboo shoots, prepared mixed and seasoned vegetables, and the Japanese rice delicacy known as Kamameshi. This segment delivers its merchandise directly to supermarket chains, hotels, hospitals, and restaurants, augmented by sales through independent third-party distributors. Globally, ONE Bio Corp. exports its products to Japan, various Southeast Asian nations, European markets, and North America. Founded in 2000, the company was rebranded from ONE Holdings, Corp. to ONE Bio Corp. in November 2009 and is based in Aventura, Florida.
Führung
- Jian Ming ChanChairman of the Advisory Board & Chief Scientist
- Jerold SieganGeneral Counsel
- Min ZhaoDirector & President of China Operations
- CEO
- Jian Ming Chan
- Mitarbeitende
- 358
- Hauptsitz
- Aventura, FL, US
- Sektor
- Basic Materials
- Branche
- Chemicals - Specialty
- Börsengang
- 15. Sept. 2009
- Website
- onebiocorp.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.